Keyphrases
Puumala Virus
100%
Hantavirus Infection
77%
Finland
50%
Virus Infection
43%
University Hospital
33%
Disease Severity
29%
Hemorrhagic Fever with Renal Syndrome
27%
Whole Blood
25%
Rhesus Blood Group
25%
ABO Blood Group
25%
Disease Biomarker
25%
Chromium
25%
Lymphoid Malignancies
25%
Healthcare Utilization
25%
Register Study
25%
Hip Arthroplasty
25%
Health Care Costs
25%
Heparin-induced Thrombocytopenia
25%
Autoimmune Heparin-induced Thrombocytopenia
25%
Delayed Onset
25%
Hemostasis
25%
Coagulopathy
25%
Cobalt
25%
Metal-on-metal
25%
Blood Count
25%
Treatment Costs
25%
Haemophilia Care
25%
Hemophilia
18%
Acute Kidney Injury
16%
Bleeding Symptoms
14%
Leukocytes
13%
Coagulation Abnormalities
12%
Endocrine Abnormalities
12%
Peripheral Hormones
12%
Acute Phase
12%
Annualized Bleeding Rate
12%
Factor Replacement Therapy
12%
Severe Thrombocytopenia
11%
Confidence Interval
11%
Thrombocytopenia
10%
Adult Patients
10%
Platelet Transfusion
10%
Heparin Therapy
10%
Intracranial Bleeding
10%
Heparin
10%
Metal Ion Measurement
9%
Hazard Ratio
8%
Tampere
8%
Non-O Blood Group
8%
Blood Group O
8%
Medicine and Dentistry
Hantavirus Infection
77%
Virus Infection
50%
Puumala Virus
50%
Hemorrhagic Fever with Renal Syndrome
36%
Hantavirus
32%
Platelet
32%
Acute Kidney Injury
30%
Leukocyte
30%
Disease Severity
30%
Bleeding
28%
Haemophilia
25%
Blood Group Rh
25%
Blood Group ABO System
25%
Lymphoma
25%
Biological Marker
25%
Hip Arthroplasty
25%
Cohort Analysis
25%
Health Care Cost
25%
Heparin-Induced Thrombocytopenia
25%
Coagulopathy
25%
Blood Stasis
25%
Thrombocytopenia
24%
Symptom
20%
Blood Group O
20%
Metal Ion
18%
Hip
18%
Blood Group
15%
Nephropathia Epidemica
12%
Clinical Feature
12%
Thrombosis
12%
Heparin
12%
Disseminated Intravascular Coagulation
12%
Inflammatory Mediator
12%
Low Platelet Count
12%
Thromboembolism
10%
Blood Donor
10%
Capillary Leak Syndrome
10%
Haemophilia A
8%
Hazard Ratio
8%
Disease
8%
Hormone Deficiency
8%
Hypogonadism
8%
D-Dimer
8%
Thyroxine
8%
Thyroid Function
8%
Hypothyroidism
8%
Implant
6%
Adverse Event
6%
Substitution Therapy
5%
B Cell
5%